S100A9 exerts insulin-independent antidiabetic and anti-inflammatory effects
Science Advances · 05.01.2024 · 10 (1)
DOI: 10.1126/sciadv.adj4686 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 05.01.2024. Verfasst von Gloria Ursino und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Physiology and Metabolism, University of Geneva, 1211 Geneva, Switzerland. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Hypoglycemia, Hyperglycemia. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Type 1 diabetes mellitus (T1DM) is characterized by insulin deficiency leading to hyperglycemia and several metabolic defects. Insulin therapy remains the cornerstone of T1DM management, yet it increases the risk of life-threatening hypoglycemia and the development of major comorbidities. Here, we report an insulin signaling–independent pathway able to improve glycemic control in T1DM rodents. Co-treatment with recombinant S100 calcium-binding protein A9 (S100A9) enabled increased adherence to glycemic targets with half as much insulin and without causing hypoglycemia. Mechanistically, we demonstrate that the hyperglycemia-suppressing action of S100A9 is due to a Toll-like receptor 4–dependent increase in glucose uptake in specific skeletal muscles (i.e., soleus and diaphragm). In addition, we found that T1DM mice have abnormal systemic inflammation, which is resolved by S100A9 therapy alone (or in combination with low insulin), hence uncovering a potent anti-inflammatory action of S100A9 in T1DM. In summary, our findings reveal the S100A9-TLR4 skeletal muscle axis as a promising therapeutic target for improving T1DM treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cell Physiology and Metabolism, University of Geneva, 1211 Geneva, Switzerland.
- Diabetes Center of the Faculty of Medicine, University of Geneva, 1211 Geneva, Switzerland.
- Department of Molecular Biology, University of Geneva, 1211 Geneva, Switzerland.
- Service of Endocrinology, Diabetes, Nutrition and Therapeutic patient education, Geneva University Hospital, 1205 Geneva, Switzerland.
- Center for Hypothalamic Research, Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA.
ORCID-Profile: Gloria Ursino, Giulia Lucibello, Anna Höfler, Christelle Veyrat-Durebex, François R Jornayvaz, Andreas Boland, Giorgio Ramadori, Roberto Coppari
Zitieren
APA
Ursino, G., Lucibello, G., Teixeira, P. D. S., Höfler, A., Veyrat-Durebex, C., Odouard, S., Visentin, F., Galgano, L., Somm, E., Vianna, C. R., Widmer, A., Jornayvaz, F. R., Boland, A., Ramadori, G., & Coppari, R. (2024). S100A9 exerts insulin-independent antidiabetic and anti-inflammatory effects. Science Advances, 10(1). https://doi.org/10.1126/sciadv.adj4686
Vancouver
Ursino G, Lucibello G, Teixeira PDS, Höfler A, Veyrat-Durebex C, Odouard S, et al. S100A9 exerts insulin-independent antidiabetic and anti-inflammatory effects. Science Advances. 2024;10(1). doi:10.1126/sciadv.adj4686
BibTeX
@article{Ursino2024,
author = {Ursino, Gloria and Lucibello, Giulia and Teixeira, Pryscila D S and Höfler, Anna and Veyrat-Durebex, Christelle and Odouard, Soline and Visentin, Florian and Galgano, Luca and Somm, Emmanuel and Vianna, Claudia R and Widmer, Ariane and Jornayvaz, François R and Boland, Andreas and Ramadori, Giorgio and Coppari, Roberto},
title = {S100A9 exerts insulin-independent antidiabetic and anti-inflammatory effects},
journal = {Science Advances},
year = {2024},
volume = {10},
number = {1},
doi = {10.1126/sciadv.adj4686}
}
EUVIMED